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1607-551X/Copyright ª 2015, KaohsiuAbstract Ascorbic acid bound to KMUP-1 and sildenafil were examined for their antioxidant
effects on vascular endothelium growth factor (VEGF) and endothelium nitric oxide synthase
(eNOS) in hypoxic pulmonary artery (PA). Inhaled KMUP-1 and oral sildenafil released NO from
eNOS. The effect of buffered L-ascorbic acid, alone and bound to KMUP-1 or sildenafil, for
treating pulmonary arterial hypertension (PAH) is unclear. In this study, the antioxidant capac-
ity of ascorbic acid increased the beneficial effects of KMUP-1 on PAH. KMUP-1A and sildenafil-
A (5 mg/kg/d) were administered to hypoxic PAH rats. Pulmonary artery blood pressure, and
VEGF, Rho kinase II (ROCK II), eNOS, soluble guanylate cyclase (sGC-a), and protein kinase G
expression in lung tissues were measured to link PAH and right ventricular hypertrophy. Hyp-
oxic rats had higher pulmonary artery blood pressure, greater PA medial wall thickness and
cardiac weight, and a higher right ventricle/left ventricle þ septum [RV/(LVþS)] ratio than
normoxic rats. Oral KMUP-1A or sildenafil-A for 21 days in hypoxia prevented the rarefaction
of eNOS in immunohistochemistry (IHC), reduced the IHC of VEGF in PAs, restored eNOS/pro-
tein kinase G/phosphodiesterase 5A; unaffected sGC-a and inactivated ROCK II expression
were also found in lung tissues. In normoxic PA, KMUP-1A/Y27632 (10mM) increased eNOS
and reduced ROCK II. ROCK II/reactive oxidative species was increased and eNOS was reduced
after long-term hypoxia for 21 days. KMUP-1A or Y27632 blunted ROCK II in short-term hypoxiceclare no conflicts of interest.
of Pharmacology, School of Medicine, College of Medicine, Kaohsiung Medical University, 100 Shih-
n.
w (I.-J. Chen).
5.02.005
ng Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
242 J.-R. Wu et al.FPA at 24 hours. L-Ascorbic acid þ L-sodium ascorbate (40, 80mM) buffer alone directly inhibited
the IHC of VEGF in hypoxic PA. Finally, KMUP-1A or sildenafil-A reduced PAH and associated
right ventricular hypertrophy.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
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The aim of this study was to investigate the protective ef-
fects of buffered ascorbic acid alone and ascorbic acid
bound to KMUP-1/sildenafil, targeting vascular endothelium
growth factor (VEGF) and endothelium nitric oxide synthase
(eNOS) to affect pulmonary arterial hypertension (PAH).
The VEGF family of proteins increased in hypoxia injury is
an important angiogenic cytokine with critical roles in
angiogenesis. In particular, VEGF has an important role in
approaches, designed to evaluate patient prognosis for
pulmonary proliferative disease, including PAH [1,2].
The role of VEGF in pulmonary arteries (PAs) via oxida-
tive stress and the antioxidant effects of buffered L-ascor-
bic acid alone or bound to KMUP-1/sildenafil was explored
to define their benefits [3]. Whether KMUP-1-L-ascorbate
(7-{2-[-4(2-chlorophenyl)piperazinyl] ethyl}-1,3-
dimethylxanthine,L-ascorbic acid; KMUP-1A; Fig. 1) can
inhibit hypoxia-induced PAH, and if so, how its action is
comparable to that of sildenafil ascorbate (sildenafil-A;
Fig. 1), has implications for the actions of VEGF and colo-
calized Rho kinase II (ROCK II), eNOS, and phosphodies-
terase 5A (PDE5A), and soluble guanylate cyclase (sGC-a) in
lung tissues and PAs [4,5].
Oxidative stress reflects an imbalance between the
manifestation of reactive oxygen species (ROS) and the
ability of the biological system or antioxidant environment
to detoxify the resulting damage. KMUP-1 bound to acidic
type simvastatin was found to inhibit bleomycin-induced
lung fibrosis/inflammation and has been reported to inhibit
GRPRs in monocrotaline-induced chronic PAH [6,7]. L-
Ascorbic acid bound to inhaled KMUP-1 or sildenafil is sug-
gested to increase or sustain their antioxidant activities in
the pulmonary respiration system for prophylaxis against
PAH-associated diseases.igure 1. Chemical structuresHypoxia is a common cause of persistent PAH in new-
borns and is also associated with endothelial dysfunction
and abnormal pulmonary vascular remodeling. The GTPase
RhoA and ROCK II have been implicated in the pathogenesis
of persistent PAH, but their contribution to endothelial
remodeling and function is not well known. ROCK II
reportedly mediates hypoxia-induced capillary angiogen-
esis, a previously unrecognized but potentially important
adaptive response [8]. Sustained inhibition of the RhoA/
ROCK II pathway throughout the period of hypoxic exposure
attenuated PAH and prevented remodeling in blood vessels
without enlarging the lumen diameter [4].
Hypoxic PAH has been attributed to structural changes in
the pulmonary vasculature, including narrowing of the
vascular lumen and loss of vessels, which produces a fixed
increase in resistance [4]. PAH is characterized by reduced
eNOS, increased ROCK II expression, and decreased pul-
monary vascular density [8]. eNOS downstream signaling in
the cyclic guanosine monophosphate (cGMP) pathway for
inhibiting PAH includes the expression of sGC-a and protein
kinase G (PKG), which have been reported to be down-
regulated by hypoxia [9]. In hypoxic PAH, NO releasing
disturbances can be caused by downregulation of eNOS and
upregulation of ROCK II [10]. Vascular contractility and
resistance are regulated by eNOS, sGC-a, PDE5A, and RhoA/
ROCK II expression in the cGMP pathway [11]. Moreover, co-
localized eNOS/sGC-a/PDE5A expressions in PA are involved
in sildenafil’s inhibition of PAH [12]. Although sildenafil and
the ROCK inhibitors Y27632 and fasudil have been beneficial
in PAH through inactivation of RhoA/ROCK II, the relation-
ship between the colocalized VEGF/ROCK II and treatment
with buffered L-ascorbate/L-ascorbic acid remains to be
investigated [13].
VEGF is required for the growth of pulmonary endothe-
lial cells and to repair the damage caused by hypoxia [14].of KMUP-1A and sildenafil-A.
Hypoxic pulmonary artery 243One study found pulmonary VEGF expression to be mark-
edly decreased in an experimental model of persistent PAH,
mimicking the structural and functional abnormalities of
PA, and that exogenous treatment with VEGF improved PAH
by upregulating the production of NO [15]. The controversy
between increasing and decreasing VEGF for the treatment
of PAH in hypoxia remains to be resolved. VEGF exerts its
biological effects primarily on endothelial cells in hypoxia
[16]. Hypoxia regulation via VEGF has been described as
occurring through the induction of PI3K/Rho/ROCK and c-
Myc, which is a target of the PI3K/ROCK II signaling pathway
and which can regulate VEGF promoter through its binding
element [16].
The expression of RhoA/ROCK II is surprisingly close to
VEGF signaling. Previous reports found that RhoA or ROCK II
inhibition diminishes VEGF-induced polymerization of actin
[17]. The ROCK inhibitor fasudil inhibits VEGF-induced
angiogenesis in vitro and in vivo [18]. These findings
imply a close relationship between RhoA/ROCK II and VEGF.
The therapeutic benefits of ROCK inhibitor in hypoxia are
partly attributable to the restoration of PKG-mediated
vasodilatation [19]. cGMP-dependent inhibition of Rho/
ROCK II by KMUP-1A is thus a competitive strategy to the
ROCK inhibitor fasudil and cGMP enhancer sildenafil-A for
inactivating ROCK II to treat hypoxic PAH [18e20].
ROS are produced from endogenous sources, most notably
the oxidative metabolism in mitochondria, and from exoge-
nous sources such as ionizing radiation and hypoxia. ROS can
induceDNAdamageviahypoxiaandcontribute toPAH [20,21].
To evaluate theprotective effects of KMUP-1A and sildenafil-A
against hypoxia-induced oxidative damage, it is essential to
determine ROS production during hypoxia in lung tissues, be-
side producing other hypoxic or normoxic organ injuries. To
confirm whether KMUP-1A and sildenafil-A could ameliorate
vascular narrowing and ventricular hypertrophy, we verified
our findings by observing changes in PA wall thickness,
immunohistochemical (IHC) staining of VEGF/eNOS involved
in PA endothelium, and hematoxylin and eosin (H&E) staining
of the right ventricle/left ventricleþ intraventricular septum
[RV/(LVþS)] by microscopy [5].
Materials and methods
KMUP-1A and sildenafil-A
KMUP-1A and sildenafil-A were synthesized by combining
KMUP-1 or sildenafil base with L-ascorbic acid at an equal
mole ratio followed by crystallization in ethanol as previ-
ously described [5]. Sildenafil citrate was supplied by Cadila
Healthcare Ltd. (Maninagar, India) and purified as previ-
ously described [4]. We hypothesized that L-ascorbic acid
bound to KMUP-1 or sildenfil would be a useful antioxidant
preparation for the pulmonary airway system [6].
Animal hypoxia
Long-term oral administration of KMUP-1A/sidenafil-A
(5 mg/kg/d) for 21 days were followed for male Wistar
rats (200e250 g; National Laboratory Animal Breeding and
Research Center Taipei, Taiwan) by gavage at 8 o’clock
every morning. For our in vivo hypoxic experiments, 10-week-old male Wistar rats were divided into four equal
groups: a normoxia group without KMUP-1A/sildenafil-A, a
hypoxia group, a hypoxia þ KMUP-1A group, and a
hypoxia þ sildenafil-A group. This study focused on the
beneficial effects of L-ascorbic acid/L-ascorbate buffer,
KMUP-1A and sildenafil-A in hypoxia. All rats were main-
tained on a 12-hour light/12-hour dark cycle at 25  1C
and were provided with food and water ad libitum. The
normoxia group was housed in standard normoxic condi-
tions, and the other three treated groups were continuously
housed in a hypoxic chamber (10% O2), except for a 30-
minute interval each day when the chamber was cleaned,
during which a normoxic gas mixture was prepared from
compressed air [21]. In our in vitro short-term experiment,
isolated rat PA was grown under normoxia (20% O2) or
hypoxia (1% O2) at 37C for 24 hours. The heart weight and
body weight ratio (HW/BW) of the rats treated with either
KMUP-1A or sildenafil-A were measured on the 21st hypoxic
day. All animal care and the experimental protocols of this
study were approved by the Animal Care and Use Commit-
tee of the Kaohsiung Medical University, Kaohsiung, Taiwan.
Hemodynamic measurements
On the 21st day, the rats were administered with urethane
(1.25 g/kg, i.p.), and their chests were opened. Their
breathing was normal, and their body temperature was
maintained at 37C. Using a pressure transducer (Model
P50; Gould Electronics, Cleveland, OH, USA) connected
with a Pressure Processor Amplifier (Model 13-4615-52;
Gould Electronics), we recorded the mean pulmonary
arterial pressure (MPAP) and heart rates of the rats from
the femoral artery and mean artery blood pressure from the
PA. The animals for testing were sacrificed by urethane
overdose at the end of experiments.
Western blotting analysis
Whole right lung tissues of hypoxia-treated and untreated
rats were isolated, cut into small chips, and placed into an
extraction buffer (Tris 10mM, pH 7.0, NaCl 140mM, phe-
nylmethylsulfonyl fluoride 2mM, dithiothreitol 5mM, NP-40
0.5%, pepstatin A 0.05mM, leupeptin 0.2mM) for protein
extraction, and then centrifuged at 12,500g for 30 minutes.
To measure the protein expression levels, the total proteins
were extracted and Western blotting analyses were per-
formed as described previously [6]. Briefly, the protein
extract was boiled to a ratio of 4:1 with sample buffer (Tris
100mM, pH 6.8, glycerol 20%, sodium dodecyl sulfate 4%
and bromophenol blue 0.2%). Electrophoresis was per-
formed using 10% sodium dodecyl sulfate-polyacrylamide
gel (2 hours, 100 V, 40 mA, 50 mg protein per lane). Sepa-
rated proteins were transferred to polyvinylidene difluoride
membranes treated with 5% fat-free milk powder to block
the nonspecific IgGs (90 minutes, 100 V) and incubated for 1
hour with specific protein antibody. The blot was then
incubated with antimouse or antigoat IgG linked to alkaline
phosphatase (1:1000) for 1 hour. Immunoreactive bands
were visualized using horseradish peroxidase-conjugated
secondary antibodies with subsequent ECL detection (GE
Healthcare Bio-Sciences Corp., Piscataway, NJ, USA).
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Biotechnology, Lake Placid, NY, USA), sGC-a (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), PDE5A (BD Tansduc-
tion, San Jose, CA, USA), PKG (Calbiochem, San Diego, CA,
USA), ROCK II (Upstate Biotechnology), RhoA (Santa Cruz
Biotechnology), and the loading control protein b-actin
(Sigma-Adrich, St. Louis, MO, USA) were used in our West-
ern blot analyses.
To examine the short-term action of treatments in
hypoxia, the second branches of the main rat PA rings were
isolated and cut into 2e3-mm pieces for rapid incubation
with KMUP-1A/sildenafil-A (10mM) and Y27632 (10mM) for 24
hours in wells of an incubation plate in a hypoxic (1% O2) or
normoxic (10% O2) atmosphere. Western blotting analysis
was performed as in lung tissue.
Histological examination and H&E staining
The right lobes of the rat lungs and hearts, including RV/
(LVþS), of six rats from each group were cut and soaked in
formalin, dehydrated through graded alcohols, and
embedded in paraffin wax. The lung tissue specimens fixed
with formalin were embedded in paraffin, cut into 4-mm-
thick sections, and subjected to H&E staining prior to ex-
amination by light microscope. In our histopathological
study, we measured the thickening of the medial wall of the
small intrapulmonary arteries under an Eclipse TE2000-S
microscope (Nikon, Tokyo, Japan). In heart tissues, 4-mm-
thick paraffin sections were cut from paraffin-embedded
tissue blocks, deparaffinized by immersion in xylene and
rehydrated. The slices were then dyed with H&E. After
gently rinsing with water, each slide was dehydrated
through graded alcohols and finally soaked in xylene twice.
Morphology, immunohistochemistry, and right
heart index
We obtained the right lungs and hearts of six rats from each
group. The samples were fixed in formalin and embedded in
paraffin, and 4-mm sections were mounted onto Thermo
Scientific Superfrost slides. Right lung and heart sections
were stained with H&E for assessment of vascular and car-
diac morphology. In each group, medial thickness (mm) and
medial wall area (calculated as the area between the in-
ternal elastic lamina and the adventitia of themuscular layer
of PAs) weremeasured using an Eclipse TE2000-S microscope
(Nikon) coupled to a color video camera (Nikon). The relative
cardiacweight of theRV/(LVþS) ratio (i.e., right heart index)
was calculated using RV/(LVþS). Measurements were ob-
tained with the Histolab software (Microvision Instruments,
Evry, France). Six measurements of PA in each animal were
taken and averaged. Immunohistochemistry (IHC) of eNOS
and VEGF antibody were selected for right lung section
immunostaining.
IHC of eNOS and VEGF in PA walls
To make sure that ascorbic acid can protect against
hypoxia-induced endothelium proliferation by antioxidant
activity, sodium ascorbate þ ascorbic acid (20mM, 40mM,
and 80mM) was incubated at an equal molar ratio with thePA rings under short-term hypoxia for 24 hours to determine
the IHC of VEGF and eNOS.
NO metabolite (NOx) production
On the 21st day of standard diet supplementation and
treatment or protection, production of NO was determined
by metabolite nitrate þ nitrite (NOx) in homogenized lung
tissue using the Griess method [3,4]. The three-step Greiss
test converts nitrate (NO3
) into nitrite (NO2
), giving a total
NO2
 concentration from a standard calibration curve. The
lung tissues were homogenized, washed with phosphate-
buffered saline, and incubated in lysis buffer in addition
to a protease inhibitor cocktail (Sigma-Aldrich, St. Louis,
MO, USA) to lung proteins. The homogenized lung tissue
(100 mL) was incubated at 37C for 30 minutes with N-2-
hydroxyethylpiperazine-N0-ethane sulfonic acid buffer
(50mM, pH 7.4), flavin adenine dinucleotide (5mM), nico-
tinamide adenine dinucleotide phosphate (0.1mM),
distilled water (290 mL), and nitrate reductase (0.2 U/mL)
to convert nitrate into nitrite. The samples were then
incubated (25C,10 minutes) with Griess reagent [N-(1-
naphthyl)-ethylenediamine: 0.2% (w/v), sulfanilamide: 2%
(w/v), solubilized in double-distilled water: 95%; phos-
phoric acid: 5% (v/v)] and the absorbance measured at
540 nm. The levels of nitrite in the lung tissues were cali-
brated and compared to a sodium nitrite (0e150 mL) stan-
dard curve. Six independent experiments were carried out,
and data are reported as the mean  standard error of the
mean.
ROS production
On the 21st day of standard diet supplementation and
treatments or protection, pulmonary ROS was measured
using 20-70-dichlorofluorescein (H2DCF-DA; Molecular Probe,
Grand Island, NY, USA). Briefly, 10 mL of homogenized lung
tissue was diluted 100-fold with cold phosphate-buffered
saline and labeled with 5 mmol/L 20-70-dichlorofluorescein,
and the mixture was incubated at 37C for 30 minutes fol-
lowed by centrifugation at 90g for 5 minutes. Fluorescence
was measured at 485 nm excitation and 530 nm emission to
determine the concentration of H2O2 (FLUOstar Galaxy,
Offenburg, Germany) [20].
Compounds
The anti-eNOS antibody was obtained from BD Biotech-
nology (Sigma-Aldrich Co., New York, NY, USA), the anti-
PKG antibodies were from Santa Cruz Biotechnology, and
anti-sGC-a1, b-actin antibodies, and Y27632 were obtained
from Sigma Co. KMUP-1 HCl was synthesized in our labora-
tory [4]. The salt form of KMUP-1-ascorbate (7-{2-[4-(2-
chlorobenzene) piperazinyl] ethyl}-1, 3- dimethyl xanthi-
neascorbic acid; KMUP-1A) and sildenafil-A (5 mg/kg) was
used throughout this study. KMUP-1A or sildenafil-A (syn-
thesized from BNo.: RSK/616; Cadila Healthcare) was dis-
solved in vehicle (distilled water containing 0.5% methyl
cellulose). Dilutions of KMUP-1A, sildenafil-A, and L-ascor-
bic acid/L-ascorbate (L-sodium ascorbate) were made with
distilled water and then centrifuged at 1000g for 10
Hypoxic pulmonary artery 245minutes. All other reagents used were of analytical grade or
higher and were obtained from commercial sources. In the
in vitro test, L-ascorbic acid/L-ascorbate (Sigma-Aldrich)
were considered as antioxidants.
Statistical analysis
The results were expressed as the mean  standard error.
Statistical differences were determined with independent
and paired Student t test in unpaired and paired samples,
respectively. Whenever a control group was compared with
more than one treated group, one-way analysis of variance
(ANOVA) or two-way repeated-measures ANOVA was used.
When ANOVA showed a statistical difference, the Dunnett’s
or StudenteNewmaneKeuls test was applied. A p value <
0.05 was considered significant in all experiments. Analysis
of the data and plotting of the figures were done using
SigmaPlot software (version 8.0; SPSS Inc., Chicago, IL,
USA) and SigmaStat (version 2.03; SPSS Inc.) run on an IBM-
compatible computer.
Results
KMUP-1A and sildenafil-A
Fig. 1 shows that KMUP-1A and sildenafil-A were synthe-
sized by combining KMUP-1 or sildenafil base with L-ascorbic
acid at an equal mole ratio.
Hypoxic animal chamber
The upper panel of Fig. 2 shows the rats living in a plastic
chamber under a chronic hypoxic condition, which is an
animal model for experiments.
Blood pressure, heart weight, and PAH
In the lower panel of Fig. 2, the MPAP of normoxic and
hypoxic rats was 12.9  0.9 mmHg and 26.5  0.6 mmHg
(n Z 6), respectively (Fig. 2A and 2B). During the 21-day
treatment of hypoxic rats with KMUP-1A or sildenafil-A
(5 mg/kg/d, p.o.), PAH development was markedly atten-
uated to 16.9  1.1 mmHg and 19.8  0.7 mmHg (n Z 6),
respectively, on the last day (Fig. 2C and 2D). Both mean
artery blood pressure and heart rate were not significantly
changed by either KMUP-1A or sildenafil-A. The HW/BW
ratio of rats treated with KMUP-1A or sildenafil-A was
significantly different from that of nontreated rats after 21
days (Table 1).
H&E staining on lung and heart tissues
Fig. 3(I) shows the cross section of PA, in which vascular
muscularization or remodeling was represented by an in-
crease in PA wall thickness (WT %) in hypoxic rats, detected
on Day 0 and Day 21, following the right lung resection.
Small pulmonary arterial morphology (< 150mM) was highly
improved in KMUP-1 ascorbate-treated rats. As shown in
Fig. 3A, sections stained with H&E indicated that muscu-
larization of the distal PA was significantly lower in hypoxicrats treated with KMUP-1A (Fig. 3C) and sildenafil-A
(Fig. 3D) than those given vehicle only (Fig. 3B).
Fig. 3(II) demonstrates the cross section of the rat heart.
Fig. 3G shows that hypoxia increased the RV/(LVþS) weight
ratio, i.e., right heart index, to 184.6  0.7%, compared to
normoxic rats (Fig. 3E). KMUP-1A and sildenafil-A reduced
the thickness of RV compared to the hypoxic state. KMUP-
1A reduced the right heart index to 117.4  2.6%
(p < 0.01) and sildenafil-A decreased the right heart index
to 145.3  0.4% (p < 0.01; Fig. 3F and 3H).
Relative PA wall thickness (WT %)
As shown in Fig. 4A, sections stained with HE indicated
muscularization of the distal PA. A quantitative analysis of
the relative PA wall thickness showed that hypoxia
increased the PA wall thickness to 165.8  5.4% (p < 0.01),
but this condition was reversed by treatment with KMUP-1
[Hypoxia þ KMUP-1A (5 mg/kg/d)] or sildenafil
[Hypoxia þ Sildenafil-A (5 mg/kg/d)] for 21 days. KMUP-1A
inhibited hypoxia-induced PA wall thickness to 81.3  2.3%
(p < 0.01); sildenafil-A inhibited hypoxia-induced PA wall
thickness to 81.3  2.3% (p < 0.01; Fig. 5A).
Right ventricular hypertrophy
KMUP-1A and sildenafil-A reduced the thickness of RV
compared to the hypoxic state. As shown in Fig. 4B, hypoxia
increased the relative RV/(LVþS) weight ratio (i.e., right
heart index) to 184.6  0.7%, compared to normoxic rats.
KMUP-1A reduced the right heart index to 117.4  2.6%
(p < 0.01), and sildenafil-A decreased the right heart index
to 145.3  0.4% (p < 0.01), compared to hypoxic rats.
IHC of eNOS and VEGF in PA wall
Morphometric immunostaining of lung sections of long-term
hypoxia animals demonstrated a marked decrease of eNOS
located mainly in PA endothelium, and this decrease was
correlated with medial thickening (Fig. 5A). VEGF immu-
nostaining was also mainly located in the endothelium and
more significantly in the smooth muscle, compared to
arterial sections without immunostaining reactivity used as
controls (Fig. 5B). Treatments with KMUP-1A or sildenafil-A
restored the decay of eNOS and reduced VEGF immuno-
staining reactivity. L-Ascorbic/L-ascorbate (40, 80mM)
reduced the IHC of VEGF immunostaining reactivity and
restored eNOS activity in PA, indicating an oxidative stress
defense against short-term acute hypoxia (Fig. 5C).
Pulmonary eNOS/sGC-a/PKG/PDE5A after long-term
hypoxia
Western blotting analysis demonstrated that eNOS and sGC-
a in lung tissues of hypoxia-treated rats were increased by
KMUP-1A to 139.7  16.9% (p < 0.05) and 40.4  8.4%
(p < 0.05; Group 3) and by sildenafil-A to 102.6  7.7% and
72.0  4.7% (Group 4), respectively, compared to normoxia
control (Fig. 6A and 6B). KMUP-1A was more potent than
sildenafil-A in increasing eNOS, and sildenafil was more
potent than KMUP-1A in increasing sGC-a expression.
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Animal model under chronic hypoxia for 21 days
Figure 2. Animal chamber of chronic hypoxia for recording PABH. Upper panel: rats were placed in transparent plastic chambers
and adapted to chronic hypoxia by 10% oxygen for 21 days. Lower panel: rats were exposed to (A) 20% O2 (normoxia) or (B) 10% O2
(hypoxia), and (C) treated with KMUP-1 [Hypoxia þ KMUP-1A (5 mg/kg/d)] or (D) sildenafil [Hypoxia þ Sildenafil-A (5 mg/kg/d)] for
21 days. Animals were anesthetized and the blood pressure (BP) and heart rate were measured through cannulated PA in an open-
chest state. Arrow indicates the valve opening of a three-way stopcock connected to a cannula for recording BP.
Table 1 Effects of treatments on rat hemodynamics in hypoxia for 21 days.
Normoxia Hypoxia Hypoxia þ KMUP-1A
(5 mg/kg/d)
Hypoxia þ Sildenafil-A
(5 mg/kg/d)
BW (g) 421.4  7.7 237.8  8.3* 288.3  7.9# 275.0  10.4#
HR (bpm) 375.8  14.0 380.7  12.0 342.1  15.9 352.2  36.4
MPAP (mmHg) 12.9  0.9 26.5  0.6* 16.9  1.1# 19.8  0.7#
MABP (mmHg) 91.8  1.3 90.4  3.7 89.7  2.9 93.6  3.1
HW/BW (mg/g) 3.6  0.1 5.1  0.2* 4.1  0.3# 4.2  0.2#
Data are presented as mean  SEM.
*p < 0.05 compared with Normal.
#p < 0.05 compared with 21 days of hypoxia.
bpmZ beats/min; BWZ body weight; HRZ heart rate; HW/BWZ heart weight/body weight; MABPZ mean arterial blood pressure;
MPAP Z mean pulmonary arterial pressure; SEM Z standard error of the mean.
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Figure 3. Morphologic demonstration of pulmonary artery
(PA) caused by long-term hypoxia and treatments. Represen-
tative hematoxylin and eosin (H&E) staining demonstrates the
structure of PA in lung tissues. Rats were exposed to (A) 20% O2
(normoxia) or (B) 10% O2 (hypoxia), and treated with (C) KMUP-
1 [Hypoxia þ KMUP-1A (5 mg/kg/d)] or (D) sildenafil
[Hypoxia þ Sildenafil-A (5 mg/kg/d)] for 21 days. For clarity, a
photomicrograph displaying a high degree of medial thickening
after 21 days of hypoxia is shown. (I) Lung tissue.
Magnification,  400. Scale bar Z 100 mm. (II) Cross section of
heart tissue. Black scale bar Z 1 mm. Red bar indicates wall
thickness.
Hypoxic pulmonary artery 247Whereas KMUP-1A clearly increased PKG to 85.0  12.9%,
sildenafil-A only brought about insignificant increases in
PKG to 68.7  3.7%, compared to nontreated hypoxic rats
(Fig. 6C). PDE5A expression was decreased to 43.8  12.6%
(p < 0.05) in hypoxia. However, neither agent was found to
further reduce the expression of PDE5A. Surprisingly, both
KMUP-1A and sildenafil-A restored PDE5A expression to
76.9  4.9% and 109.0  3.8% of normal levels, compared to
nontreated hypoxic animals (p < 0.05) (Fig. 6D).Pulmonary VEGF/ROCK II expression after long-
term hypoxia
The expression of ROCK II and VEGF was increased to
144.7  12.6% (p < 0.05) and 168.9  24.6% (p < 0.05),
respectively, by 21 days of hypoxia. Treatment with KMUP-
1A or sildenafil-A during this period reduced the hypoxia-
induced increase of ROCK II to 50.32  7.9% (p < 0.01)
and 97.4  10.9%, respectively (Fig. 6E). VEGF expression
was reduced by KMUP-1A and sildenafil-A (120.9  22.2%
and 125.7  22.5%, respectively), compared to the non-
treated hypoxic rat group (Fig. 6F). KMUP-1A was found to
decrease ROCK II more potently than sildenafil-A, but these
two agents were almost equally able to inhibit VEGF
expression.eNOS, ROCK II, and VEGF expression in PA after
short-term hypoxia
Besides the IHC information on eNOS and VEGF above,
Fig. 7A shows that the expression of eNOS in normoxic PA
rings in 24 hours was increased to 117.9  9.1% (p < 0.05)
by KMUP-1A (10mM) and increased to 114.1  12.3%
(p < 0.05) by the ROCK inhibitor Y27632 (10mM). The
expression of ROCK II was decreased to 48.2  5.5%
(p < 0.05) by KMUP-1A and to 67.5  14.8% by Y27632
(p < 0.01), in comparison with nontreated controls.
Fig. 7B shows that the expression of ROCK II in isolated
hypoxic PA at 24 hours increased to 180  10.2% (p < 0.01)
and eNOS% was decreased to 60  8.3% (p < 0.05). Treat-
ment with KMUP-1 ascorbate returned ROCK II to 140  9.0%
(p < 0.05) and eNOS to 45  3.0%. Treatment with Y27632
returned ROCK II to 150  13.1% and eNOS to 50  4.7%
compared to normoxic control levels.
Fig. 7C shows that sGC-a expressed no significant dif-
ference between hypoxia and normoxia, indicating its
resistance to hypoxia. Fig. 7D shows that VEGF was
increased by hypoxia but was inhibited by KMUP-1A and
sildenafil-A.Pulmonary NOx after long-term hypoxia
A Griess reagent analysis showed that the basal levels of
NOx in lung tissue significantly decreased to 59.8  3.7%,
compared to 100% of the control group, at 21 days of hyp-
oxia (Fig. 8A). The decreased levels of NOx in hypoxic lung
tissues were significantly restored by KMUP-1A and
sildenafil-A to 86.3  17.3% and 84.5  14.2%, respectively
(p < 0.01 vs. control).Pulmonary ROS after long-term hypoxia
Fig. 8B shows that hypoxia increased ROS in lung tissues as
detected by H2DCF-DA assay using fluorescence analysis.
Hypoxia increased the dichlorofluorescein to 165  1.0%,
compared to normoxia control; KMUP-1A and sildenafil-A
reduced the hypoxia-induced dichlorofluoroscence to
70  1.0% and 115  2.5%, compared to hypoxia control for
21 days, respectively.
Figure 4. Cross section of lung tissues or heart and oral treatment for 21 days for quantitative analysis of relative wall thickness
of pulmonary artery (PA) and weight ratio of right ventricular (RV) hypertrophy. (A) Hypoxia caused a significant increase in PA wall
thickness compared to (B) normoxia. Treatment with (C) KMUP-1A and sildenafil-A decreased the wall thickness to near-normal
conditions. Wall thickness was calculated by equation. For the analysis of wall thickness, animals were exposed to 20% O2 (nor-
moxia) or 10% O2 (hypoxia), and treated with KMUP-1 [Hypoxia þ KMUP-1A (5 mg/kg/d)] or sildenafil [Hypoxia þ Sildenafil-A (5 mg/
kg/d)] for 21 days. For clarity, a photomicrograph displaying a high degree of thickening after 21 days of hypoxia is shown.
Magnification, 400. Scale barZ 100 mm. Right ventricle/(left ventricle þ septum) [RV/(LVþS)] weight ratio of heart in pulmonary
arterial hypertension (PAH) was reduced by treatments with KMUP-1A or sildenafil-A, [/Y indicates increase/decrease. Data are
presented as mean  standard error of the mean; *p < 0.05, compared with normoxia; #p < 0.05, compared with hypoxia.
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L-Ascorbic acid or L-ascorbates was first described to exhibit
antioxidant activity on pulmonary endothelium by inhibit-
ing VEGF and restoring eNOS in a hypoxia study. We suggest
that this antioxidant activity is particularly useful for
inhibiting hypoxic PAH resulting from proliferation of
endothelium. The accurate mimicry of human PAH by ani-
mal models is indispensable for testing the usefulness of
drug treatments. To determine if KMUP-1A/sildenafil-A al-
ters rat PA endothelial cell proliferation, we tested altered
VEGF/ROCK II/eNOS/PKG/PDE5A signaling in PA under
short-term acute hypoxia in vitro for 24 hours and long-
term chronic hypoxia in vivo for 21 days. We further
examined the role of VEGF/ROCK II/eNOS in long-term
hypoxia-induced PAH and associated right ventricular hy-
pertrophy (RVH), before and after treatment with KMUP-
1A/sildenafil-A. We confirmed that KMUP-1A/sildenafil-A
suppressed both VEGF and ROCK II after long-termhypoxia, and thus inhibited PAH and associated RVH. The
ability to do this over long-term administration was evi-
denced by reversed pulmonary eNOS, sGC-a, PKG, and in-
hibition of ROCK II and PDE5A expression as well as by
inhibition of VEGF and restoration of eNOS as shown by IHC.
The inhibition of cGMP-specific phosphodiesterase leads
to the downstream phosphorylation of Rho, interfering with
the expression of ROCK II and the phosphorylation of IRAG,
eventually inhibiting IP3/IRAG-mediated Ca2þ release from
endoplasmic reticulum [19]. KMUP-1A/sildenafil-A, dis-
playing eNOS/sGC/PKG-enhancing activity, may interfere
with ROCK II activation and the intracellular events of Ca2þ
release to reduce PABH.
Mechanisms that impair proliferation in hypoxic PA
endothelium are poorly understood. One way of treating
PAH is to reduce vascular resistance by inhibiting ROCK II
and Ca2þ sensitization, and another is to relax smooth
muscles by increasing the accumulation of cGMP through
the activation of eNOS/sGC-a and inhibition of PDE5A [22].
Figure 5. Pulmonary IHC of eNOS and VEGF in PA of lung tissues. Representative IHC for eNOS (A/C) and VEGF (B/D) in PA
endothelium of lung tissues. Animals were exposed to 20% O2 (normoxia) or 10% O2 (hypoxia), treated with KMUP-1
[Hypoxia þ KMUP-1A (5 mg/kg/d)] or sildenafil [Hypoxia þ Sildenafil-A (5 mg/kg/d)] for 21 days. In isolated PA, hypoxia þ L-so-
dium ascorbate (40mM) þ L-ascorbic acid (40mM) was incubated with tissues for 24 hours, as a short-time hypoxia model in in vitro.
(D) indicates thicker brown IHC staining and () indicates abated IHC staining. eNOS Z endothelium nitric oxide synthase;
IHC Z immunohistochemistry; PA Z pulmonary artery; VEGF Z vascular endothelium growth factor.
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Figure 6. Effects of treatments on long-term hypoxia-induced eNOS, sGC-a, PKG, PDE5A, ROCK II, and VEGF expression in lung
tissue. Animals were exposed to 20% O2 (hormoxia) or 10% O2 (hypoxia), and treated with KMUP-1A (5 mg/kg/d) or sildenafil-A
(5 mg/kg/d) for 21 days. Data are presented as mean  SEM; *p < 0.05, compared with normoxia; #p < 0.05, compared with
hypoxia; ※ p < 0.05, compared to by sildenafil-A. eNOS Z endothelium nitric oxide synthase; PDE5A Z phosphodiesterase 5A;
PKGZ protein kinase G; ROCK IIZ Rho kinase II; SEMZ standard error of the mean; VEGFZ vascular endothelium growth factor.
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be used to treat PAH by increasing cGMP in PA inspired
us to search for a new cGMP-dependent type ROCK inhib-
itor. We have used KMUP-1 HCl previously [4,5]. In this
study, we confirmed that hypoxia could inducedownregulation of eNOS/PDE5A and was restored by KMUP-
1A/sildenafil-A. eNOS restoration increased the production
of NO to activate PKG. The restoration of eNOS may result
from the enhanced antioxidant activity of KMUP-1A/sil-
denafil-A.
Figure 7. Effects of treatments on PA ring expression of ROCK II, sGC-a, and VEGF after short-term hypoxia. Animals exposed to
2% O2 for 24 hours were cotreated with KMUP-1 ascorbate (10mM) or Y27632 (10mM) for 24 hours. Data are presented as mean  SEM;
*p ＜0.05, compared to control (CTL) in normoxia (20% O2). (A/B) ROCK II expression, eNOS expression; (C) sGC-a expression; (D)
VEGF expression. All values are mean  SEM. ***p < 0.001 versus control group; ##p < 0.01 versus KMUP-1A or sildenafil-A group.
PA Z pulmonary artery; ROCK IIZ Rho kinase II; SEM Z standard error of the mean; sGC-a Z soluble guanylate cyclase;
VEGF Z vascular endothelium growth factor.
Hypoxic pulmonary artery 251PAH can be caused by impairment of cGMP downstream
PKG signaling, resulting from long-term hypoxia, in which
ROCK II retards PKG-induced vasodilatation [22]. ROCK II
has also been associated with vascular resistance, which is
attributed to Ca2þ sensitization [16]. KMUP-1A/sildenafil-A
inhibited the expression of ROCK II, suggesting that it may
reduce PAH-related vascular resistance through Ca2þ
desensitization. The concomitant increases in ROCK II
expression and Ca2þ sensitization, increases in arterial
[Ca2þ]i, and decrease in oxygenation together may syner-
gistically produce sustained PAH in long-term hypoxia.
Therefore, we suggest that KMUP-1A or sildensil-A attenu-
ates PAH through the restoration of endothelial eNOS,
which may be downstream of inactivated ROCK II and
associated Ca2þ desensitization in PA smooth muscle cells
as previously described [4,5]. In PA, ROCK II and eNOS
expression display a contrary-regulation relationship in
hypoxic vascular endothelium [23]. KMUP-1A/sildenfil-A
increased eNOS expression and inactivated ROCK II, sug-
gesting that they might prolong the duration of vascular
relaxation and reduction of vascular resistance through the
cGMP pathway. Unfortunately, sGC stimulation totally re-
verses hypoxia-induced pulmonary vasoconstriction alone
and combined with dual endothelin-receptor blockade in a
porcine model; thus, KMUP-1A and sildenafil-A cannot
obtain the benefits of this resistance of sGC-a [24].KMUP-1A/sildenafil-A inhibited ROCK II and VEGF
expression, immunohistochemically demonstrated in
endothelial and nonendothelial cells, indicating anti-
hyperplasia activity as evidenced by histologic/morphologic
observations. However, one study has suggested that the
administration of exogenous VEGF may inhibit PAH through
VEGF receptor-mediated NO signaling in newborn lambs
[25]. The difference between those findings and ours may
be related to the fact that they were studying newborn
animals deficient of VEGF and we were studying PAH in a
long-term hypoxic state in mature rats, with elevated VEGF
via hypoxia [26]. Inactivation of ROCK II in long-term hyp-
oxia by KMUP-1A or sildenafil-A might increases the pro-
duction and bioavailability of endothelium-derived NO.
Upregulation of eNOS by inactivated ROCK II in the endo-
thelium may, therefore, be an important mechanism un-
derlying the cardiovascular protective activity of KMUP-1A/
sildenafil-A in PA and right ventricle.
KMUP-1A/sildenafil-A’s increase of PKG and decrease of
ROCK II expression indicate an indirect cGMP-dependent
inactivation of ROCK II, in contrast to direct ROCK II inhi-
bition by Y27632 [27]. Interestingly, PKG inhibitor pre-
vented KMUP-1A and Y27632-induced decreases of ROCK II
and increase of PKG in normoxia, suggesting that there is a
downstream relationship between ROCK II and PKG [5]. We
found eNOS and PKG to be increased and ROCK II decreased
Figure 8. Effects of long-term treatments on pulmonary
production of NOx and ROS. (A) Lung tissues of animal treated
with KMUP-1A and sildenafil-A for 21 days showed raised
release of NO, represented by NOx, compared to nontreat-
ment. Griess reagent analysis showed that the basal levels of
NOx in lung tissue. (B) Free radical-scavenging effects of KMUP-
1A and sildenafil-A by H2DCF-DA assay and measurements of
ROS production. Lung tissues of animal treated with KMUP-1A
and sildenafil-A for 21 days. The level of pulmonary ROS was
detected by the H2DCF-DA assay using fluorescence analysis. In
(A), all values are mean  SEM. **p < 0.01 versus normoxia
control group; ##p < 0.01 versus KMUP-1A or sildenafil-A group.
In (B), all values are mean  SEM. **p < 0.01 versus normoxia
control group; ##p < 0.01 versus KMUP-1A or sildenafil-A group.
H2DCF-DA Z 20-70-dichlorofluorescein; NOx Z metabolite
nitrate þ nitrite; SEM Z standard error of the mean;
ROS Z reactive oxygen species.
252 J.-R. Wu et al.in both KMUP-1A and Y27632-treated normoxic PA,
compared to nontreated normoxic PA, regardless of
whether there was a decrease in expression of PDE5A in
hypoxia. In a previous study, we observed that KMUP-1
decreased the expression of PDE5A in U46619-induced
acute PAH, whereas PDE5A was increased in
monocrotaline-induced PAH [4,5]. In long-term chronic
hypoxia, KMUP-1A/sildenafil-A restored PDE5A to near-normal levels, suggesting that increased PKG by KMUP-1A/
sildenafil-A and even Y27632 may largely result from the
upregulation of eNOS and accompanied inhibition of ROCK
II. It has been suggested that ROCK II negatively regulates
eNOS phosphorylation through the inhibition of protein ki-
nase B/Akt in endothelial cells [5,28].
NOS is localized in a variety of cells of the respiratory
tract, including endothelial, epithelial, and inflammatory
cells, providing the sources of NO production. In healthy
situations, NO derived from eNOS activation seems to be
predominant, because low levels of NO produced by eNOS
control the airway smooth muscle tone [29]. Long-term
chronic inhibition of ROCK II by inhaled KMUP-1A/
sildenafil-A on the epithelium or in the endothelium of
the airway can activate or increase the expression of eNOS
to increase NO production, leading to pulmonary and even
PA relaxation [5,29,30].
ROS can cause massive tissue disruption, widespread
lipid protein oxidative modification, enzyme release,
mitochondrial injury, release of proinflammatory cyto-
kines, apoptosis, necrosis, and ultimately organ failure
[31]. Overproduction of ROS results in oxidative stress,
causing tissue damage [24]. NO donors KMUP-1 and sil-
denafil, two antioxidants with NO releasing properties, can
capture free radical oxygen to produce NOx. Thus, drug
treatment with KMUP-1A/sildenafil-A inhibits hypoxia-
induced ROS, potentially inhibiting ROS-associated PA
proliferation and PAH [6]. Long-term hypoxic PAH can lead
to RVH, a result of vascular resistance by PA [32]. In
hypoxia-treated rats, the level of MPAP, right ventricular
division, left ventricular division, septum, and small pul-
monary arterial morphologic changes were highly
improved. KMUP-1A might cause a specific PA vasodilata-
tion and antihyperplasia effect, leading to a decrease in
MPAP. Here, KMUP-1A/sildenafil-A inhibited PAH, combining
eNOS/cGMP-enhancing and ROCK II-suppressing activity in
vascular smooth muscle cells to inhibit long-term hypoxia-
induced PAH and vascular remodeling. Several other
studies have suggested that activation of the RhoA/ROCK II
pathway contributes to both vasoconstriction and pulmo-
nary smooth muscle cell hypertrophy via long-term hyp-
oxia. Inactivation of ROCK II can attenuate PAH by
inhibiting smooth muscle cell proliferation and by vaso-
relaxation. Similarly, expression of eNOS contributes to
both the local regulation of vascular smooth muscle tone
and the inhibition of ROCK II, leading to a reduction of cell
proliferation in smooth muscle [33].
Regarding the difference between long-term hypoxia
in vivo and short-term hypoxia in vitro, neither KMUP-1A
nor Y27632 could significantly restore eNOS in 24-hour
hypoxia, although both were able to significantly suppress
the expression of ROCK II and VEGF, indicating that the
biosynthesis of eNOS required more time. We suggest that
PA ring VEGF was upregulated in short-term acute hypoxia
and accompanied by an increase in ROCK II but not eNOS.
Obviously, the pharmacologic strategy of treatment with
KMUP-1A/sildenfil-A is to prevent the worsening of vascular
eNOS rarefaction and VEGF/ROCK II activation of PA in long-
term hypoxia. We used hypoxic animals for testing and
looked the normoxic expression as a 100% control; VEGF
was obviously increased in the former, easily reflecting the
effects of KMUP-1A/sildenafil-A [34].
Hypoxic pulmonary artery 253sGC-a is the best described receptor of NO, resistant to
hypoxia [35,36]. However, enhanced levels of oxygen rad-
icals in long-term hypoxia may inactivate endogenous NO by
formation of the highly reactive intermediate peroxynitrite
or directly by oxidizing the sGC-a heme iron from the
ferrous (Fe2þ) state into the ferric (Fe3þ) state [33]. KMUP-
1A/sildenafil-A may restore eNOS expression to release NO,
leading to increased second messenger cGMP, which in turn
results in vascular vasodilation via a cGMP/PKG signaling
pathway in long-term hypoxic PAH, unrelated to hypoxic
sGC-a [35].
KMUP-1A displays both (1) receptor-mediated and (2)
cGMP-dependent RhoA/ROCK II inactivation, resulting in
inhibition of PA contractility in hypoxia. The former
pathway for inhibiting PAH via GPCR (G proteinecoupled
receptor) has been demonstrated by an ET1-receptor-
dependent pathway [7]. KMUP-1A suppression of PAH has
the merits of both (1) an ET1-receptor type GPCR antago-
nist and (2) cGMP-dependent RhoA/ROCK II inactivation.
Sildenafil-A possibly covers the (2) pathway only. KMUP-1A
was found to be superior to sildenafil-A in inhibiting ROCK
II and enhancing eNOS after long-term chronic hypoxia.
Sildenafil-A is more potent than KMUP-1A in restoring sGC-a
expression for unknown reasons. KMUP-1A inactivated ROCK
II more potently than Y27632 after short-term acute hyp-
oxia and restored PKG more potently than sildenafil-A after
long-term chronic hypoxia owing to the additive action of
both pathways. Both KMUP-1A and sildenafil-A protected
PDE5A and PKG from downregulation via chronic hypoxia.
Downregulation of PKG and PDE5A via long-term hypoxia
might be restored by NO production from eNOS activated by
KMUP-1A or sildenafil-A [35,36].
KMUP-1A/sildenafil-A expression of eNOS overwhelmed
their PDE5A inhibition, contributing to the accumulation of
cGMP in hypoxic PA [11]. Both KMUP-1A/sildenafil-A
inhibited chronic hypoxia-induced VEGF expression,
demonstrating that they had important antiproliferation,
antihyperplasia, and antiremodeling effects on PA. KMUP-
1A/sildenafil-A suppression of VEGF was found to play an
important role in inhibiting vascular wall thickness in
chronic hypoxic PA.
Supplementation with L-ascorbic acid has been shown to
decrease DNA damage in animal studies [13]. The histologic
morphologic observations in this study confirm the benefits
of L-ascorbates of KMUP-1 and sildenafil for protecting PA
from endothelium proliferation via VEGF/eNOS, evidenced
by IHC. L-Ascorbic acid þ L-ascorbate buffer incubated with
PA rings certainly inhibit short-term acute hypoxia-induced
upregulation of VEGF and rarefaction of eNOS in IHC
morphologic observation. L-Ascorbic acid bound to KMUP-1
or sildenafil is thus suggested to be a rational combination
for improving the treatment of PAH, hypoxia-induced pul-
monary endothelium hyperproliferation, or oxidative
stress-induced disease.
KMUP-1A/sildenafil-A’s effects on eNOS, sGC-a, PKG,
ROCK II, and VEGF expression displayed an association
among the expression of these proteins that might make
the reversal of PAH possible by inhibiting vascular remod-
eling, hyperplasia, and RVH after long-term hypoxia. Buff-
ered L-ascorbic acid contributed significant benefits in
combination with KMUP-1A and sildenafil-A via its intrinsic
antioxidant activity. In conclusion, both KMUP-1A andsildenafil-A prevent the development of PAH by suppressing
VEGF/ROCK II and restoration of eNOS in lung tissues or PAs.
Antioxidant buffered L-ascorbic acid could enhance the
benefits of KMUP-1 and sildenafil by inhibiting hypoxia-
induced oxidative stress. Inhaled KMUP-1A or sildenafil-A
should be better localized in lung tissues and remain to
be investigated in human patients [2].Acknowledgments
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